As on Thursday, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) started slowly as it slid -4.93% to $36.42, before settling in for the price of $38.31 at the close. Taking a more long-term approach, NAMS posted a 52-week range of $14.06-$41.47.
Nevertheless, stock’s Earnings Per Share (EPS) this year is 42.13%. This publicly-traded company’s shares outstanding now amounts to $113.17 million, simultaneously with a float of $73.74 million. The organization now has a market capitalization sitting at $4.13 billion. At the time of writing, stock’s 50-day Moving Average stood at $32.51, while the 200-day Moving Average is $23.59.
NewAmsterdam Pharma Company NV (NAMS) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. NewAmsterdam Pharma Company NV’s current insider ownership accounts for 34.97%, in contrast to 61.88% institutional ownership. According to the most recent insider trade that took place on Sep 15 ’25, this organization’s Director bought 660 shares at the rate of 23.70, making the entire transaction reach 15,639 in total value, affecting insider ownership by 3,028,524. Preceding that transaction, on Sep 09 ’25, Company’s Chief Accounting Officer sold 150,000 for 25.83, making the whole transaction’s value amount to 3,874,017. This particular insider is now the holder of 15,000 in total.
NewAmsterdam Pharma Company NV (NAMS) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.39 per share during the current fiscal year. NewAmsterdam Pharma Company NV’s EPS increase for this current 12-month fiscal period is 42.13% and is forecasted to reach -1.70 in the upcoming year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
Let’s observe the current performance indicators for NewAmsterdam Pharma Company NV (NAMS). It’s Quick Ratio in the last reported quarter now stands at 12.57. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 117.19.
In the same vein, NAMS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.04, a figure that is expected to reach -0.40 in the next quarter, and analysts are predicting that it will be -1.70 at the market close of one year from today.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Through scrutinizing the latest numbers posted by the [NewAmsterdam Pharma Company NV, NAMS], it can be observed that its last 5-days Average volume of 1.16 million was better the volume of 0.94 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 57.11% While, its Average True Range was 46.71.
Raw Stochastic average of NewAmsterdam Pharma Company NV (NAMS) in the period of the previous 100 days is set at 78.78%, which indicates a major rise in contrast to 29.58% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 2.55 that was higher than 1.65 volatility it exhibited in the past 100-days period.
